The Johnson & Johnson Q1 2009 earnings call highlights solid performance amidst economic challenges. The company's diverse portfolio ensures stability, with focus on new product launches and cost containment. While generic competition impacts pharmaceuticals, consumer healthcare and medical devices demonstrate resilience. The stock is likely to remain stable, supported by the company's robust pipeline, cost management, and commitment to innovation, resulting in a neutral impact in the short term. [0]